CA2404374A1 - Utilisation de sels metalliques pour stabiliser des compositions a base de taxane - Google Patents

Utilisation de sels metalliques pour stabiliser des compositions a base de taxane Download PDF

Info

Publication number
CA2404374A1
CA2404374A1 CA002404374A CA2404374A CA2404374A1 CA 2404374 A1 CA2404374 A1 CA 2404374A1 CA 002404374 A CA002404374 A CA 002404374A CA 2404374 A CA2404374 A CA 2404374A CA 2404374 A1 CA2404374 A1 CA 2404374A1
Authority
CA
Canada
Prior art keywords
acid
composition
carrier
taxane
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002404374A
Other languages
English (en)
Inventor
Kai Zhang
Gregory A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Baker Cummins Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharmaceuticals Inc filed Critical Baker Cummins Pharmaceuticals Inc
Publication of CA2404374A1 publication Critical patent/CA2404374A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions contenant un taxane, un excipient, et un sel métallique d'un acide. L'invention concerne également des procédés permettant de stabiliser des compositions de taxane/excipient, et de réduire la dégradation des taxanes, par exemple, pendant un stockage. Ces procédés impliquent l'incorporation du sel métallique dans la composition de taxane, ou le préchauffage de l'excipient avec ledit sel métallique, éventuellement associé à d'autres prétraitements.
CA002404374A 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane Abandoned CA2404374A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19180200P 2000-03-24 2000-03-24
US60/191,802 2000-03-24
PCT/US2001/009416 WO2001072300A1 (fr) 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane

Publications (1)

Publication Number Publication Date
CA2404374A1 true CA2404374A1 (fr) 2001-10-04

Family

ID=22706985

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002404374A Abandoned CA2404374A1 (fr) 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane
CA002404370A Abandoned CA2404370A1 (fr) 2000-03-24 2001-03-23 Compositions a base de taxane et procedes d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002404370A Abandoned CA2404370A1 (fr) 2000-03-24 2001-03-23 Compositions a base de taxane et procedes d'utilisation

Country Status (7)

Country Link
EP (2) EP1315484A1 (fr)
JP (2) JP2003528141A (fr)
KR (2) KR20030019328A (fr)
AR (2) AR027715A1 (fr)
AU (2) AU2001247726A1 (fr)
CA (2) CA2404374A1 (fr)
WO (2) WO2001072300A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1461056A4 (fr) * 2001-11-26 2006-01-25 Supergen Inc Procede de preparation et d'utilisation d'huile de ricin polyoxyethylee dans des compositions pharmaceutiques
AU2002360816A1 (en) * 2001-12-28 2003-07-24 Ivax Research, Inc. Taxane based compositions and methods of use
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
JP5198858B2 (ja) * 2004-08-03 2013-05-15 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 腸内投与のための担体
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
CA2597223A1 (fr) * 2005-02-10 2006-08-17 Sindan Pharma Srl Procede de purification d'un agent de surface
EP1690551A3 (fr) 2005-02-10 2006-10-18 Sindan Pharma Srl Purification d'un tenside par ultrafiltration
JP2008543789A (ja) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー ドセタキセルの液体薬学的処方物
EP1893159B1 (fr) 2005-06-17 2015-09-30 Vital Health Sciences Pty Ltd. Support comprenant un ou plusieurs dérivés de di- et/ou monophosphate d'agents de transfert d'électrons
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
EP2531047A4 (fr) 2010-02-05 2014-03-19 Phosphagenics Ltd Vecteur comprenant du phosphate de tocophéryle non neutralisé
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
CA2798180A1 (fr) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Formulations non aqueuses de pro-emulsions a base de taxane et procedes de fabrication et d'utilisation de ces formulations
US9345683B2 (en) * 2010-11-08 2016-05-24 Cadila Pharmaceuticals Limited Pharmaceutical composition of taxoids
WO2012122586A1 (fr) 2011-03-15 2012-09-20 Phosphagenics Limited Nouvelle composition
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
MX2019006845A (es) 2016-12-21 2019-10-15 Avecho Biotechnology Ltd Proceso.
CN110585189B (zh) * 2019-09-05 2022-12-30 广东艾时代生物科技有限责任公司 三尖杉宁碱在制备治疗疟疾药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
CN1225262A (zh) * 1998-12-09 1999-08-11 延边香料研究所 一种含有紫杉醇的抗癌药物
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Also Published As

Publication number Publication date
KR20030019327A (ko) 2003-03-06
CA2404370A1 (fr) 2001-10-04
AR027715A1 (es) 2003-04-09
WO2001072299A1 (fr) 2001-10-04
WO2001072300A1 (fr) 2001-10-04
JP2003528141A (ja) 2003-09-24
JP2003528142A (ja) 2003-09-24
AU2001247726A1 (en) 2001-10-08
EP1408956A1 (fr) 2004-04-21
KR20030019328A (ko) 2003-03-06
AU2001247739A1 (en) 2001-10-08
EP1315484A1 (fr) 2003-06-04
AR027714A1 (es) 2003-04-09

Similar Documents

Publication Publication Date Title
CA2404374A1 (fr) Utilisation de sels metalliques pour stabiliser des compositions a base de taxane
US11931321B2 (en) Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same
JP2595458B2 (ja) タキサン類の誘導体を基とする新規組成物
US20090221688A1 (en) Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same
EP3213746B1 (fr) Composition pharmaceutique pour administration orale comprenant un taxane
NZ512686A (en) Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
Esposito et al. Lipid nanostructures for antioxidant delivery: A comparative preformulation study
AU2007246077A1 (en) Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
US7699987B2 (en) Stabilized formulation
EP2034957B1 (fr) Composition pharmaceutique pour administration orale
AU776993B2 (en) Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
AU2003256786B2 (en) Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
CN112716914B (zh) 白蛋白包裹的卡巴他赛阳离子纳米脂质载体及其制备方法
JP2885668B2 (ja) テプレノン製剤
AU2004203394A1 (en) Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof

Legal Events

Date Code Title Description
FZDE Dead